Denosumab (Prolia, Xgeva, and Biosimilars) for Subcutaneous Injection
Customize your policy alerts
Sign up for all goldcoasthealthplan policy alerts
Know when goldcoasthealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Part B coverage and prior authorization for physician-administered subcutaneous denosumab, including Prolia, Xgeva, and listed biosimilars, for Medicare Advantage members receiving treatment for osteoporosis, cancer-related fracture prevention, multiple myeloma or solid-tumor bone metastases, giant cell tumor of bone, or hypercalcemia of malignancy.
The policy added the Enoby, Xtrenbo, Bosaya, and Aukelso denosumab biosimilars.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.